TY  - CONF
AU  - Capdevila, J.
AU  - Landolfi, S.
AU  - Hernando, J.
AU  - Teule, A.
AU  - Garcia-Carbonero, R.
AU  - Custodio, A.
AU  - Cubillo, A.
AU  - Alonso-Gordoa, T.
AU  - Carmona-Bayonas, A.
AU  - Crespo, G.
AU  - Blanco, M.
AU  - Viudez, A.
AU  - La Casta, A.
AU  - Sevilla, I.
AU  - Segura, A.
AU  - Lopez, C.
AU  - Benavent Vinuales, M.
AU  - Nuciforo, P.
AU  - Manzano, J. L.
PY  - 2021
DO  - 10.1016/j.annonc.2021.08.189
SN  - 0923-7534
UR  - https://hdl.handle.net/10668/27028
T2  - Annals of oncology
AB  - Background.Previously reported treatment efficacy with durvalumab (D) plus tremelimumab (T) showed limited activity in patients (pts) with well differentiated neuroendocrine tumors (NETs). However, primary endpoint was achieved in grade 3 (G3)...
LA  - en
PB  - Elsevier
KW  - Humans
KW  - Neuroendocrine Tumors
KW  - Survival Rate
KW  - Carcinoid Tumor
KW  - Gastrointestinal Neoplasms
KW  - Treatment Outcome
KW  - Lung
KW  - durvalumab
KW  - tremelimumab
KW  - Platinum
KW  - Prospective Studies
KW  - Carcinoma, Neuroendocrine
KW  - Treatment Outcome
TI  - Durvalumab plus tremelimumab in patients with grade 3 neuroendocrine neoplasms of gastroenteropancreatic origin: Updated results from the multicenter phase II DUNE trial (GETNE 1601)
TY  - conference output
VL  - 32
ER  -